Provectus Pharmaceuticals, Inc. (OTC-BB: PVCT), a biopharmaceutical company focused on developing cancer and psoriasis treatments using the Rose Bengal compound, similar to companies like Dendreon Corporation (Nasdaq: DNDN) and BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), could help advanced melanoma patients with its PV-10 treatment.

Provectus Pharmaceuticals, Inc. (OTC-BB: PVCT) is a biopharmaceutical company focused on developing cancer and psoriasis treatments using the Rose Bengal compound. Recently, The University of Florida Shands Cancer Center published an article titled “Advanced Melanoma Patients May Benefit from PV-10” that highlight the promising results from its Phase II study of PV-10 for metastatic melanoma.

To view the entire article, click on this link:

http://cancer.ufl.edu/2010/11/16/advanced-melanoma-patients-may-benefit-from-pv-10/

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designation from the FDA for its melanoma indication. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed its Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.